Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance

• Sanne J. de Haart,
• Lisa Holthof,
• Willy A. Noort,
• Monique C. Minnema,
• Maarten E. Emmelot,
• Tineke Aarts-Riemens,
• Parul Doshi,
• Kate Sasser,
• Huipin Yuan,
• Joost de Bruijn,
• Anton C.M. Martens,
• Niels W.C.J van de Donk,
• Henk M. Lokhorst,
• Richard W.J. Groen,
• Tuna Mutis

Affiliations

Sanne J. de Haart

Department of Clinical Chemistry and Hematology, University Medical Center Utrecht, the Netherlands

Lisa Holthof

Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands

Willy A. Noort

Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands

Monique C. Minnema

Department of Hematology, University Medical Center Utrecht, the Netherlands

Maarten E. Emmelot

Department of Hematology, University Medical Center Utrecht, the Netherlands

Tineke Aarts-Riemens

Department of Clinical Chemistry and Hematology, University Medical Center Utrecht, the Netherlands

Parul Doshi

Janssen Research & Development, Spring House, PA, USA

Kate Sasser

Janssen Research & Development, Spring House, PA, USA

Huipin Yuan

Xpand Biotechnology BV, Bilthoven, the Netherlands

Joost de Bruijn

Xpand Biotechnology BV, Bilthoven, the Netherlands

Anton C.M. Martens

Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands

Niels W.C.J van de Donk

Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands

Henk M. Lokhorst

Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands

Richard W.J. Groen

Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands

Tuna Mutis

Department of Clinical Chemistry and Hematology, University Medical Center Utrecht, the Netherlands;Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands